BPC-157 Complete Research Guide: Mechanisms, Applications & Studies
Research Notice: This article covers research on KLOW Stack research peptide blend — available from Palmetto Peptides for laboratory use only.
Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.
Research Disclaimer: BPC-157 is sold by Palmetto Peptides strictly as a research compound for in vitro and laboratory use only. It is not intended for human or veterinary consumption, administration, or therapeutic use.
BPC-157 is one of the most extensively studied synthetic peptides in preclinical research. Researchers can order BPC-157 research peptide from Palmetto Peptides with full lot-specific COA documentation. For combined tissue repair research, the BPC-157 + TB-500 Wolverine Stack is also available.
Last Updated: March 20, 2026 | Reading Time: Approximately 3 minutes | Author: Palmetto Peptides Research Team
Quick Answer
BPC-157 is one of the most extensively studied synthetic peptides in preclinical research. Researchers can order BPC-157 research peptide from Palmetto Peptides with full lot-specific COA documentation. For combined tissue repair research, the BPC-157 + TB-500 Wolverine Stack is also available.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino acid sequence — derived from a region of the human gastric juice protein BPC. The peptide sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It has no known endogenous receptor and does not correspond to any naturally occurring full-length protein fragment. Its effects in laboratory models have been studied across an unusually wide range of tissue systems for a single research compound.
Mechanism of Action in Laboratory Models
BPC-157 does not operate through a single defined molecular mechanism. Laboratory research has identified several proposed pathways:
- Nitric oxide (NO) system modulation: Multiple studies implicate the NO pathway as a central mediator, particularly in GI and vascular research models
- Growth factor receptor upregulation: Studies have reported increases in VEGFR2 and FGFR expression in BPC-157 treated tissues in rodent models
- Tendon fibroblast activity: In vitro studies show effects on tendon fibroblast migration and collagen organization
- Dopamine system interaction: Rodent behavioral models have examined BPC-157 effects on dopamine receptor activity
Key Research Areas
Gastrointestinal Research
The earliest and most extensive BPC-157 research is in GI models. Studies in rat models of gastric ulceration, colitis, and intestinal fistula repair have consistently documented accelerated healing endpoints in BPC-157 treated groups. The compound's apparent oral activity in rodent models — unusual for a peptide — has attracted particular research interest.
Tendon and Musculoskeletal Models
Preclinical tendon transection studies in rats have shown accelerated collagen organization and biomechanical recovery in BPC-157 treated tendons. This research area is often studied in combination with TB-500 (Thymosin Beta-4), which works through a different mechanism (actin regulation). See the Wolverine Stack research guide for combined protocol context.
Neurological Models
More recent preclinical studies have explored BPC-157 in neurological injury models including traumatic brain injury and spinal cord research, as well as dopamine system dysregulation models in rodents.
Systemic Cytoprotection
BPC-157 has been studied in multiple organ protection models — including heart, liver, kidney, and lung — in response to various chemical and mechanical stressors in rodent systems.
Purity and Quality Standards for BPC-157 Research
Research-grade BPC-157 requires: HPLC purity of 98% or above, lot-specific mass spectrometry identity confirmation (expected MW: 1419.56 g/mol), and peptide content percentage reported separately. Palmetto Peptides provides full COA documentation for every lot. Related reading: research peptide purity testing standards and GHK-Cu research guide.
Reconstitution and Storage
BPC-157 reconstitutes readily in bacteriostatic water or sterile PBS at pH 7.4. Standard stock concentration: 1–2 mg/mL. Store lyophilized powder at -20°C desiccated dark (stable 24+ months). Reconstituted stocks at -80°C in single-use aliquots (stable 6–12 months). Maximum 3 freeze-thaw cycles.
Frequently Asked Questions
Is BPC-157 approved for human use?
No. BPC-157 has not received FDA approval for any human therapeutic indication. It is available strictly as a research compound for qualified laboratory use.
What is the molecular weight of BPC-157?
Approximately 1419.56 g/mol. Molecular formula: C62H98N16O22.
How does BPC-157 differ from TB-500?
BPC-157 and TB-500 (Thymosin Beta-4) are structurally unrelated peptides that work through different mechanisms. BPC-157 operates primarily through the NO system and growth factor receptor pathways; TB-500 works through actin regulation and cell motility. They are frequently studied together in combined tissue repair models.
See Also: BPC-157 and TB-500 Wolverine Stack Research Guide
Related: BPC-157 Reconstitution & Storage: Lab Protocol Guide